Retatrutide: Dosing Protocols

Investigational Status Disclaimer#

Retatrutide (LY3437943) is an investigational compound that has not been approved by the FDA or any other regulatory agency for any indication. The dosing information presented below is derived exclusively from published Phase 1 and Phase 2 clinical trial protocols. Retatrutide is not available for clinical prescription and should not be used outside of authorized clinical trials. No official prescribing information or dosing guidelines exist for this compound. This information is provided for educational and research reference purposes only.

Phase 2 Clinical Trial Dosing#

Obesity Trial (NCT04881760) -- Jastreboff et al., NEJM 2023#

The pivotal Phase 2 obesity trial, published by Jastreboff et al. in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater with at least one weight-related comorbidity) without diabetes. Participants were randomized to receive subcutaneous injections of retatrutide or placebo once weekly for 48 weeks.

The trial evaluated multiple dose levels with different escalation schedules:

Dose groups and escalation protocols:

• 1 mg group: Participants initiated treatment at 0.5 mg weekly and escalated to 1 mg at a specified timepoint, then maintained at 1 mg for the remainder of the 48-week treatment period.

• 4 mg group (two escalation schedules): Participants initiated at 0.5 mg weekly and were escalated to 4 mg over either 12 weeks or 24 weeks, allowing comparison of faster versus slower escalation schedules on tolerability and efficacy. This was an important design feature, as the pace of dose escalation directly influences the incidence and severity of gastrointestinal side effects.

• 8 mg group (two escalation schedules): Similar to the 4 mg group, participants started at 0.5 mg and escalated to 8 mg over either 12 or 24 weeks. The 8 mg dose demonstrated substantial weight loss while maintaining an acceptable tolerability profile with gradual escalation.

• 12 mg group (24-week escalation): Participants started at 0.5 mg and escalated gradually to 12 mg over 24 weeks. This was the highest dose tested and produced the most pronounced weight loss (up to 24.2% at 48 weeks), but also had the highest incidence of gastrointestinal side effects.

General escalation structure:

Type 2 Diabetes Trial -- Rosenstock et al., 2023#

The Phase 2 trial in patients with type 2 diabetes (Rosenstock et al., 2023) employed a similar dose escalation strategy. Participants had type 2 diabetes inadequately controlled with metformin alone and were randomized to multiple dose arms of retatrutide or placebo for 36 weeks of treatment. Background metformin therapy was continued.

The dose arms included target doses of 0.5 mg, 4 mg, 8 mg, and 12 mg, with similar escalation schedules starting from 0.5 mg weekly. In this population, the dosing strategy also incorporated provisions for hypoglycemia management, given the additive insulinotropic effects of retatrutide with background metformin.

Rationale for Dose Escalation#

The gradual dose escalation approach used in retatrutide clinical trials is not unique to this compound but reflects well-established principles in incretin-based therapy development. Several key considerations underpin this strategy:

GI Tolerability Adaptation#

The gastrointestinal side effects of GLP-1 receptor agonists (nausea, vomiting, diarrhea) are largely dose-dependent and are most pronounced upon initiation or dose increase. Physiological adaptation occurs over days to weeks as the gastrointestinal tract adjusts to the altered motility and secretory patterns induced by GLP-1 receptor activation. By starting at a low dose (0.5 mg) and escalating gradually, the Phase 2 protocols allowed this adaptation to occur incrementally, reducing the peak intensity of GI symptoms and improving overall treatment adherence.

The Phase 2 obesity trial specifically compared 12-week versus 24-week escalation schedules for the 4 mg and 8 mg dose groups. This direct comparison allowed assessment of whether slower escalation improved tolerability without sacrificing efficacy. The data suggested that the slower (24-week) escalation reduced early GI adverse events while achieving comparable weight loss at endpoint, supporting the use of extended escalation periods for higher target doses.

Triple Agonist Complexity#

Retatrutide's triple agonist mechanism introduces pharmacological complexity beyond that of single or dual agonists. The simultaneous engagement of GIP, GLP-1, and glucagon receptors produces overlapping and potentially additive effects on gut motility, appetite signaling, glucose metabolism, and energy expenditure. Gradual dose escalation allows the body to adapt to this multi-receptor activation progressively, rather than experiencing the full pharmacological effect of all three pathways simultaneously.

The glucagon receptor component, in particular, introduces effects on hepatic metabolism and energy expenditure that are not present in approved GLP-1 or dual agonists. Gradual escalation permits monitoring for any unexpected effects of the glucagon component as the dose increases.

Steady-State Pharmacokinetics#

With a terminal elimination half-life of approximately 6 days, retatrutide reaches steady-state plasma concentrations after approximately 4-5 weekly doses at any given dose level. The dose escalation schedule is designed so that each dose level is maintained long enough for steady state to be approached before the next escalation step. This ensures that participants are exposed to predictable and stable drug concentrations at each dose before moving to a higher level, allowing adverse events to be attributed to specific dose levels and enabling appropriate dose adjustments if needed.

Administration Details#

Route of Administration#

Retatrutide is administered by subcutaneous (SC) injection. In Phase 2 clinical trials, injections were administered in the abdomen or thigh, consistent with standard practice for incretin-based peptide therapies. The subcutaneous route allows slow absorption from the injection depot, facilitated by the C18 fatty acid modification on the peptide, which promotes local tissue interactions and self-association that contribute to the extended pharmacokinetic profile.

Injection Frequency#

Retatrutide is designed for once-weekly subcutaneous injection. The approximately 6-day elimination half-life supports this dosing frequency, achieving relatively stable plasma concentrations with acceptable peak-to-trough fluctuations. Once-weekly dosing is now the standard for modern incretin-based therapies, offering significant convenience advantages over the twice-daily (exenatide) or once-daily (liraglutide) dosing required by earlier-generation GLP-1 agonists.

Injection Technique#

While specific injection instructions for retatrutide as a commercial product do not exist (given its investigational status), the general principles for subcutaneous peptide injection apply:

• Injection sites should be rotated between the abdomen and thigh to prevent lipodystrophy or injection site reactions.
• Injections should be administered at the same time each week for consistency, though the exact timing within the week is generally flexible.
• The injection should be given into the subcutaneous tissue (not intramuscularly or intradermally).

Formulation#

The specific pharmaceutical formulation of retatrutide used in clinical trials (concentration, excipients, delivery device) has not been fully disclosed in published literature. The investigational product is provided to clinical trial sites by Eli Lilly, and formulation details are proprietary. It is expected that commercial formulation, if retatrutide receives regulatory approval, would involve a pre-filled pen device similar to those used for tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy).

Storage#

Storage conditions for the investigational product are specified in clinical trial protocols and are not publicly available for general use. Based on precedent from approved incretin peptides, the commercial product would likely require refrigeration (2-8 degrees Celsius) prior to first use, with potential for limited room-temperature storage after initial use.

Dose-Response Relationships from Phase 2 Data#

The Phase 2 obesity trial provided clear dose-response data for retatrutide:

These data demonstrate a clear dose-response relationship, with progressively greater weight loss at higher doses. The incremental benefit from 8 mg to 12 mg (approximately 2 percentage points additional weight loss) was relatively smaller than the increment from 4 mg to 8 mg (approximately 5 percentage points), suggesting that the dose-response curve may begin to plateau at the higher dose range. This observation will be important for determining the optimal therapeutic doses in the Phase 3 program.

Comparison with Approved Incretin Therapy Dosing#

For context, the dosing approaches for approved incretin-based therapies follow similar escalation principles:

Retatrutide's extended escalation period (up to 24 weeks for the highest doses) is longer than that of tirzepatide (4-20 weeks) or semaglutide (16 weeks). This may reflect the greater pharmacological potency and complexity of the triple agonist mechanism, which may require more gradual physiological adaptation. Whether the Phase 3 program will use similar or modified escalation schedules remains to be determined.

Important Safety Considerations for Dosing#

Hypoglycemia Risk#

Retatrutide enhances glucose-dependent insulin secretion through both GLP-1 and GIP receptor agonism. When used alone or with metformin (which does not typically cause hypoglycemia), the risk of significant hypoglycemia is low because the insulinotropic effect is glucose-dependent. However, if retatrutide were to be used in combination with insulin or sulfonylureas (as was permitted in the diabetes trial with appropriate dose adjustments), the risk of hypoglycemia would increase, necessitating dose reductions of the concomitant insulin or secretagogue.

Renal Considerations#

GLP-1 receptor agonists can cause dehydration through GI side effects (nausea, vomiting, diarrhea), which may exacerbate renal impairment. Adequate hydration should be maintained, particularly during the dose escalation phase when GI symptoms are most likely. Patients with moderate or severe renal impairment were generally excluded from Phase 2 trials, and renal safety data for retatrutide are limited.

Dose Adjustments#

No formal dose adjustment guidelines exist for retatrutide. In Phase 2 trials, investigators had the option of delaying dose escalation or temporarily reducing doses in response to tolerability issues. The Phase 3 program may establish more specific dose adjustment recommendations.

Evidence Gaps#

Critical dosing-related evidence gaps for retatrutide include:

• Optimal therapeutic dose: The balance between efficacy and tolerability across the tested dose range will be refined in Phase 3 trials. The approved dose(s), if regulatory approval is obtained, may differ from the Phase 2 doses tested.
• Long-term dosing: Whether dose adjustments are needed beyond 48 weeks is unknown. Weight maintenance strategies (continuing the same dose vs. dose reduction) have not been studied.
• Special populations: Dosing in elderly patients, patients with hepatic or renal impairment, and pediatric patients has not been established.
• Drug-drug interaction effects on dosing: Formal studies of concomitant medications and their effects on retatrutide pharmacokinetics and dosing have not been published.
• Switching from other therapies: Protocols for transitioning patients from approved GLP-1 agonists or tirzepatide to retatrutide have not been studied.
• Missed dose guidance: Recommendations for managing missed doses have not been established.

All dosing decisions for retatrutide are made within the context of clinical trial protocols, under medical supervision, and according to sponsor-specified guidelines. This compound is not available for clinical prescription or self-administration.

Phase 2 Dose-Response Results#

The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) provided the most detailed dose-response data available for retatrutide. The following table summarizes mean body weight reduction at 48 weeks across all dose groups:

Source: Jastreboff AM, Kaplan LM, Frias JP, et al. NEJM 2023. PMID 37366315.

Cross-Trial Context#

The 24.2% mean weight loss at the 12 mg dose was the largest reported for any anti-obesity medication at the time of publication. For indirect comparison (noting that cross-trial comparisons must be interpreted with caution due to differences in study populations, duration, and design):

Retatrutide achieved its 24.2% weight loss in a shorter treatment period (48 weeks) than the comparator Phase 3 trials, and weight loss curves had not fully plateaued at 48 weeks in the higher dose groups, suggesting additional weight loss may be achieved with longer treatment duration. However, Phase 2 results may not directly predict Phase 3 outcomes, and head-to-head trials are needed for definitive comparisons.

Tools & Resources#

Calculate your exact dose -- Use the Dosing Calculator to convert vial concentrations to injection volumes for peptide protocols.

Building a multi-peptide protocol? -- Try the Protocol Schedule Builder to plan your research timeline with retatrutide alongside other peptides.

Check stack compatibility -- Verify peptide interactions using the Stack Compatibility Checker.

Model steady-state levels -- Use the GLP-1 Saturation Calculator to visualize accumulation kinetics for once-weekly incretin agonists.

Related Dosing Guides#

• Tirzepatide Dosing Protocols -- Dual GIP/GLP-1 agonist dosing and escalation
• Semaglutide Dosing Protocols -- GLP-1 agonist dosing for obesity and T2D
• Cagrilintide Dosing Protocols -- Amylin analog dosing
• Survodutide Dosing Protocols -- Dual GLP-1/glucagon agonist dosing

Compare Retatrutide#

• Retatrutide vs Tirzepatide -- Triple vs dual agonist comparison
• Retatrutide vs Semaglutide -- Triple vs single agonist comparison
• Retatrutide vs Survodutide -- Two glucagon-containing agonists compared
• Mazdutide vs Retatrutide -- Emerging triple and dual agonist comparison
• Cagrisema vs Retatrutide -- Combination vs triple agonist comparison
• CT-388 vs Retatrutide -- Next-generation triple agonist comparison

Related Reading#

• Retatrutide overview and research guide
• Retatrutide side effects profile
• Retatrutide research evidence